1Brandt J, Khariouzov A, Listing J, et al. Six-month results of a double-blind, placebo-controlled trial of etanercept treatment in patients with active ankylosing spondylitis. Arthritis Rheum,2003, 48: 1667-1675.
2Braun J, Brandt J, Listing J, et al. Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet, 2002, 359: 1187-1193.
3Van der Heijde D, Dijkmans B, Geusens P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum, 2005, 52: 582-591.
4Breban M, Vignon E, Claudepierre P, et al. Efficacy of infliximab in refractory ankylosing spondylitis: results of a six-month openlabel study. Rheumatology (Oxford), 2002, 41: 1280-1285.
5Baraliakos X, Listing J, Brandt J, et al. Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther, 2005, 7: R439-R444.
6Garrett S, Jenkinson T, Kennedy LG, et al. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol, 1994, 21: 2286-2291.
7Van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum, 1984, 27: 361- 368.
8Calin A, Garrett S, Whitelock H, et al. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. J Rheumatol, 1994, 21: 2281-2285.
9Jenkinson TR, Mallorie PA, Whitelock HC, et al. Defining spinal mobility in ankylosing spondylitis (AS): The bath AS metrology index. J Rheumatol, 1994, 21: 1694-1698,
10Mander M, Simpson JM, McLellan A, et al. Studies with an enthesis index as a method of clinical assessment in ankylosing spondylitis. Ann Rheum Dis, 1987, 46: 197-202.
6Gorman JD, Sack KE, Davis JC Jr, et al. Treatment of ankylosing spondylitis by inhibition of tumor necrosis factor alpha. N Engl J Med, 2002, 346: 1349-1356.
7Gustot T, Lemmers A, Louis E, et al. Profile of soluble cytokine receptors in Crohn's disease. Gut, 2005, 54: 488-495.
8Van der Linden S, Valkenburg HA, Cats A. Evaluation of di-agnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum, 1984, 27 : 361-368.
9Ranganathan P. Pharmacogenomics of tumor necrosis factor an-tagonists in rheumatoid arthritis. Pharmacogenomics, 2005, 6: 481-490.
10Tung CH, Lu MC, Huang KY, et al. Association between ankylosing spondylitis and polymorphism of tumour necrosis factor receptor Ⅱ in Taiwan Residents patients. Scand J Rheumatol, 2009, 38: 395-396.
